Abstract
Cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of several drugs that are currently in clinical use. The gene encoding CYP2C19 is polymorphic with the existence of different alleles resulting in altered enzyme activity. In addition, CYP2C19 activity is also dependent on its basal expression levels determined by the transcriptional regulation. Genetic variations located in the CYP2C19 promoter region may alter the interaction of promoter with transcription factors causing variable transcription. Genetic variants may also influence the induction, inhibition of CYP2C19 and may as well affect drug-drug interactions involving CYP2C19 substrates. The role of various transcription factors and genetic variants in the promoter region of CYP2C19 regulating its expression are discussed in this review. Furthermore, induction and inhibition of CYP2C19 by various drugs in clinically meaningful drug interactions are also discussed.
Keywords: CYP2C19, transcription, promoter, transcription factor, genetic variants, induction, inhibition, drug interaction, Transcriptional Regulation, Cytochrome P450, PPIs, hydrogen bond acceptors, intermediate metabolizers, extensive metabolizers, endogenous factors, genotype-phenotype association, GRE.
Current Drug Metabolism
Title:Transcriptional Regulation of CYP2C19 and its Role in Altered Enzyme Activity
Volume: 13 Issue: 8
Author(s): Chakradhara Rao S. Uppugunduri, Youssef Daali, Jules Desmeules, Pierre Dayer, Maja Krajinovic and Marc Ansari
Affiliation:
Keywords: CYP2C19, transcription, promoter, transcription factor, genetic variants, induction, inhibition, drug interaction, Transcriptional Regulation, Cytochrome P450, PPIs, hydrogen bond acceptors, intermediate metabolizers, extensive metabolizers, endogenous factors, genotype-phenotype association, GRE.
Abstract: Cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of several drugs that are currently in clinical use. The gene encoding CYP2C19 is polymorphic with the existence of different alleles resulting in altered enzyme activity. In addition, CYP2C19 activity is also dependent on its basal expression levels determined by the transcriptional regulation. Genetic variations located in the CYP2C19 promoter region may alter the interaction of promoter with transcription factors causing variable transcription. Genetic variants may also influence the induction, inhibition of CYP2C19 and may as well affect drug-drug interactions involving CYP2C19 substrates. The role of various transcription factors and genetic variants in the promoter region of CYP2C19 regulating its expression are discussed in this review. Furthermore, induction and inhibition of CYP2C19 by various drugs in clinically meaningful drug interactions are also discussed.
Export Options
About this article
Cite this article as:
Rao S. Uppugunduri Chakradhara, Daali Youssef, Desmeules Jules, Dayer Pierre, Krajinovic Maja and Ansari Marc, Transcriptional Regulation of CYP2C19 and its Role in Altered Enzyme Activity, Current Drug Metabolism 2012; 13 (8) . https://dx.doi.org/10.2174/138920012802850146
DOI https://dx.doi.org/10.2174/138920012802850146 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action
Current Pharmaceutical Design The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders
Current Drug Delivery Magnetic Resonance Imaging in the Encephalopathic Term Newborn
Current Pediatric Reviews Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Recent Patents on Drugs Addressing Neurodegenerative Diseases
Recent Patents on Biomarkers Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Editorial: [Somatic Genome Variations: First Steps towards a Deeper Understanding of an Underappreciated Source of Biodiversity and Disease (Guest Editors: Y.B. Yurov and I.Y. Iourov)]
Current Genomics The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry The Use of Interferon-Gamma Therapy in Chronic Granulomatous Disease
Recent Patents on Anti-Infective Drug Discovery Analysis of Four Types of Leukemia Using Gene Ontology Term and Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment Scores
Combinatorial Chemistry & High Throughput Screening Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy OMICS-Derived Targets for Inflammatory Gut Disorders: Opportunities for the Development of Nutrition Related Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets Maternal Fibrinogen is Necessary for Embryonic Development
Current Drug Targets Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews Neurotransmitter Effects in Human Immunodeficiency Virus (HIV) and Simian Immuno-Deficiency Virus (SIV) Infection
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design